Clinical Trial Update: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update for Vedolizumab in moderate to severe ulcerative colitis; the study completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2014-07-18